≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback

Rhabdomyosarcoma, including Hilmo

Endpoint Browser PheWeb

C3_RHABDOMYOSARCOMA_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — C48.4|C49.4
  • Cause of death: ICD-10 — C48.4|C49.4
  • Cancer registry: Topography ICD-O-3 — ANY
  • Cancer registry: Morphology ICD-O-3 — 8900|8901|8910|8920|8963
  • Cancer registry: Behaviour codes — 3

3 out of 7 registries used, show all original rules.

65

4. Check minimum number of events

None

65

5. Include endpoints

None

65

6. Filter based on genotype QC (FinnGen only)

61

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

First used in FinnGen datafreeze
DF12

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 61 29 32
Unadjusted period prevalence (%) 0.01 0.01 0.01
Median age at first event (years) 41.82 44.53 39.37

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
65
Matched controls
650
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
130
Kela drug reimbursment
Malignant tumour
+∞
46.5
39
*
A03FA01
ATC
metoclopramide; systemic, rectal
15.7
28.0
33
40
N02AA05
ATC
oxycodone; systemic
15.8
25.0
27
28
A04AA01
ATC
ondansetron; systemic, rectal
64.1
24.1
27
7
H02AB02
ATC
dexamethasone; systemic
99.1
23.9
25
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
22.1
20
*
L03AA02
ATC
filgrastim; parenteral
262.8
19.7
19
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
41.1
19.6
24
9
L03AA13
ATC
pegfilgrastim; parenteral
243.8
18.5
18
*
R4110
NOMESCO Finland
Physiotherapy
8.2
16.7
37
90
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
16.3
15
*
WW500
NOMESCO Finland
Blood transfusion
75.2
15.6
17
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
95.6
14.2
15
*
WF002
NOMESCO Finland
Radical radiotherapy
175.1
14.0
14
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
15.7
12.7
21
19
JN4BD
NOMESCO Finland
Extensive body CT
22.0
12.6
18
11
XW000
NOMESCO Finland
Bone marrow biopsy
43.7
11.8
14
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
11.8
11
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
11.8
11
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
11.8
11
*
C49.04
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the head, face and neck rhabdomyosarcoma
+∞
11.8
11
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
6.0
11.5
43
159
159
Kela drug reimbursment
Pazopanib
+∞
10.7
10
*
ZXE20
NOMESCO Finland
More than three and less than five hours
6.7
9.8
19
38
TPX10
NOMESCO Finland
Implantation of vascular injection port
36.1
9.8
12
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
116.2
9.7
10
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.5
9.6
25
66
NFR30
NOMESCO Finland
Extended excision of soft tissue tumour of hip or thigh
+∞
9.6
9
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
9.6
9
*
A04AD12
ATC
aprepitant; systemic
+∞
9.6
9
*
C49.54
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the pelvis rhabdomyosarcoma
+∞
9.6
9
*
C49.39
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the thorax other or unspecified tumor
+∞
9.6
9
*
C49.24
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of lower extremity including hip rhabdomyosarcoma
+∞
9.6
9
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
+∞
9.6
9
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
9.6
9
*
ZXD10
NOMESCO Finland
Scheduled procedure
5.0
9.5
38
143
Z51.5
ICD-10 Finland
Palliative care
22.7
9.4
13
7
D48.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Connective and other soft tissue
32.5
8.8
11
*
WZC00
NOMESCO Finland
Treatment plan or consultation
4.7
8.8
33
117
343
Kela drug reimbursment
Pazopanib
+∞
8.5
8
*
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
+∞
8.5
8
*
QX3AT
NOMESCO Finland
Ultrasound guided biopsy of subcutaneous tissue
+∞
8.5
8
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
8.5
8
*
GD1AD
NOMESCO Finland
Thorax CT examination
13.3
8.3
14
13
ZXA00
NOMESCO Finland
Right side
4.8
8.2
26
80
WX408
NOMESCO Finland
General anesthesy, balanced
4.6
8.0
27
87
JN4AD
NOMESCO Finland
Body CT examination
14.4
7.4
12
10
A41.9
ICD-10 Finland
Sepsis, unspecified
14.4
7.4
12
10
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
7.4
7
*
C49.14
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of upper extremity including shoulder rhabdomyosarcoma
+∞
7.4
7
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
7.4
7
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
7.4
7
*
C49.34
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the thoracic rhabdomyosarcoma
+∞
7.4
7
*
QX3HE
NOMESCO Finland
Ultrsound examination of lesion close to skin
34.2
7.4
9
*
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
34.2
7.4
9
*
HA1AA
NOMESCO Finland
X-ray mammography
34.2
7.4
9
*
Z2221
NOMESCO Finland
Medical doctor
4.1
7.0
28
101
ZX112
NOMESCO Finland
Subcutaneous
25.7
6.9
9
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
4.3
6.8
23
73
ZXE00
NOMESCO Finland
One hour or less
3.9
6.8
36
158
D70.82
ICD-10 Finland
Drug-induced neutropenia
77.1
6.6
7
*
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
20.5
6.5
9
5
ZXE10
NOMESCO Finland
More than one and less than three hours
3.8
6.5
32
133
WX1BG
NOMESCO Finland
Total body MRI with high intensity magnet
+∞
6.3
6
*
Z85.8
ICD-10 Finland
Personal history of malignant neoplasms of other organs and systems
+∞
6.3
6
*
C49.49
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the abdomen other or unspecified tumor
+∞
6.3
6
*
3AA13, ,
NOMESCO Finland
+∞
6.3
6
*
B01AB05
ATC
enoxaparin; parenteral
3.9
6.3
25
89
XX3DW
NOMESCO Finland
Time consuming IT work
17.1
6.1
9
6
N05BA06
ATC
lorazepam; systemic, sublingual
12.8
6.0
10
9

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
30
15
35.76
23.26
1.8
1.1
—
—
—
0
0
40
118
7.21
14.49
7.6
3.3
—
—
—
0
0
29
67
7.01
13.34
12.0
8.9
1.11
1.26
mmol/l
1.35
29
60
43
147
6.69
12.96
3.2
1.6
—
—
—
0
0
37
132
5.19
10.01
29.3
5.6
—
—
—
0
0
17
18
12.34
9.49
4.3
2.6
26.59
22.28
s
0.66
17
18
34
119
4.89
9.29
6.2
3.1
—
—
—
0
0
36
135
4.74
8.93
5.6
1.9
—
—
—
0
0
34
124
4.65
8.70
6.3
3.1
0.15
0.34
e6/l
0.84
27
91
35
136
4.41
8.13
6.2
3.1
123.58
550.90
e6/l
0.41
27
102
23
68
4.69
7.55
2.0
2.0
—
—
—
0
0
17
30
7.28
7.07
1.2
1.1
—
—
—
0
0
30
124
3.64
6.03
7.1
2.8
7.40
7.41
ph
—
5
13
36
169
3.53
5.91
8.4
3.5
35.34
75.59
e6/l
0.68
27
109
16
34
5.89
5.80
1.6
1.4
—
—
—
0
0
17
48
4.44
5.78
25.1
15.9
—
—
—
0
0
9
7
14.64
5.77
2.1
3.4
6.34
15.83
mu/l
—
9
7
43
231
3.55
5.60
18.4
8.2
1.21
1.22
mmol/l
0.64
35
209
18
56
4.06
5.38
18.7
16.2
25.25
24.23
mmol/l
0.62
18
56
36
177
3.32
5.35
15.8
11.4
1.27
1.30
inr
—
9
49
18
60
3.77
4.85
1.8
1.7
—
—
—
0
0
20
81
3.12
3.93
4.0
2.7
475.25
541.80
mosm/kgh2o
0.76
20
69
11
26
4.87
3.71
21.7
17.7
95.65
93.66
%
1.05
11
26
13
37
4.13
3.66
7.9
13.3
112.00
124.43
g/l
1.09
13
37
10
22
5.17
3.60
19.4
19.6
—
—
—
0
0
17
67
3.08
3.47
1.5
2.1
—
—
—
0
0
8
14
6.34
3.46
1.1
1.0
—
—
—
0
0
39
241
2.55
3.29
24.6
5.5
—
—
—
0
0
18
84
2.58
2.66
1.9
1.7
—
—
—
0
0
5
7
7.61
2.59
3.4
1.4
1.60
2.20
mmol/l
—
5
7
5
7
7.61
2.59
1.2
1.0
—
—
—
0
0
17
78
2.60
2.59
2.0
2.9
164.45
262.69
ng/l
0.21
11
53
24
135
2.23
2.33
1.9
1.5
—
—
—
0
0
6
14
4.60
2.20
2.5
6.9
0.87
0.99
%
—
6
14
6
14
4.60
2.20
3.0
1.4
21.00
83.11
u/ml
—
6
14
5
10
5.31
2.11
1.2
1.1
—
—
—
0
0
6
15
4.29
2.09
3.3
6.5
1.95
1.65
%
—
6
15
38
270
1.98
1.90
31.2
5.4
0.16
0.19
e9/l
0.83
33
231
0
48
0.00
1.78
0.0
1.1
—
—
—
0
0
5
13
4.07
1.75
12.0
1.9
—
—
—
0
0
19
112
1.98
1.57
1.6
2.2
—
—
—
0
0
42
324
1.84
1.49
6.2
4.0
—
—
—
0
0
6
22
2.90
1.47
1.0
1.2
—
—
—
0
0
39
305
1.70
1.22
3.9
3.2
—
—
—
0
0
6
26
2.44
1.21
1.2
1.3
—
—
—
0
0
53
456
1.88
1.13
64.8
13.5
14.64
14.41
%
0.18
53
448
5
21
2.49
1.11
1.0
1.3
—
—
—
0
0
7
35
2.12
1.03
8.7
2.4
—
—
—
0
0
6
29
2.17
0.92
25.7
10.8
112.83
130.17
g/l
—
6
29
57
517
1.83
0.85
40.3
10.8
33.12
22.58
mg/l
1.35
50
376
10
157
0.57
0.82
1.6
2.7
—
—
—
0
0
30
236
1.50
0.82
8.6
4.5
0.00
0.00
estimate
—
8
40
5
23
2.27
0.78
2.8
4.6
—
—
—
0
0
30
238
1.48
0.78
5.7
3.1
0.00
0.00
estimate
—
7
37
10
60
1.79
0.77
1.3
1.4
—
—
—
0
0
5
24
2.17
0.76
21.0
4.4
1.26
1.24
mmol/l
—
5
18
5
25
2.08
0.74
2.4
4.5
5.62
5.03
pmol/l
—
5
20
5
26
2.00
0.72
2.4
4.5
—
—
—
0
0
5
27
1.92
0.70
2.8
6.5
24.24
24.84
mmol/l
—
5
27
17
122
1.53
0.69
5.5
3.1
—
—
—
0
0
25
195
1.46
0.69
4.1
3.2
—
5.97
—
0
18
29
233
1.44
0.69
5.8
3.2
0.00
0.00
estimate
—
8
39
0
20
0.00
0.61
0.0
1.1
—
1.85
—
0
13
0
20
0.00
0.61
0.0
1.1
—
—
—
0
0
55
505
1.58
0.59
49.9
13.9
3.91
3.98
mmol/l
1.41
55
492
55
506
1.57
0.57
49.8
13.9
138.69
139.71
mmol/l
2.82
55
495
17
131
1.40
0.48
3.4
2.9
—
—
—
0
0
8
111
0.68
0.41
5.0
3.7
—
—
—
0
0
9
66
1.42
0.41
1.1
2.0
—
—
—
0
0
6
43
1.43
0.36
1.0
1.4
—
—
—
0
0
5
37
1.38
0.24
1.4
1.9
—
—
—
0
0
14
117
1.25
0.23
5.1
3.1
0.00
0.00
estimate
—
7
36
0
11
0.00
0.21
0.0
1.5
—
2.56
—
0
6
0
10
0.00
0.21
0.0
1.3
—
3.81
—
0
5
0
12
0.00
0.21
0.0
1.2
—
9.63
—
0
6
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
15
128
1.22
0.20
3.0
2.1
67.40
96.40
u/l
0.35
15
115
7
60
1.19
0.18
7.4
8.5
—
—
—
0
0
7
85
0.80
0.15
2.3
1.4
—
—
—
0
0
54
524
1.18
0.12
24.3
10.1
—
—
—
0
0
11
125
0.86
0.11
1.2
1.6
1.08
1.49
mmol/l
1.81
11
109
58
583
0.95
0.08
62.1
16.0
6.16
6.86
e9/l
1.58
58
560
58
582
0.97
0.08
62.0
16.0
29.98
29.91
pg
0.13
58
574
58
582
0.97
0.08
64.8
16.2
122.48
136.90
g/l
7.17
58
574
58
582
0.97
0.08
62.1
16.1
4.12
4.60
e12/l
7.59
58
559
18
167
1.11
0.08
2.1
1.8
93.19
99.59
pmol/l
0.19
12
87
13
124
1.06
0.01
5.8
2.6
—
—
—
0
0
0
6
0.00
0.00
0.0
4.7
—
0.78
—
0
6
0
6
0.00
0.00
0.0
2.7
—
4.37
—
0
6
0
7
0.00
-0.00
0.0
1.9
—
107.71
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
49
1.02
-0.00
1.2
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
4.04
—
0
7
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
58
581
0.98
-0.00
62.2
16.1
243.02
253.42
e9/l
0.44
58
560
0
5
0.00
-0.00
0.0
1.8
—
0.35
—
0
5
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
54.60
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
58
581
0.98
-0.00
62.1
16.1
90.30
89.41
fl
0.66
58
573
0
5
0.00
-0.00
0.0
4.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: C3_RHABDOMYOSARCOMA_WIDE – Rhabdomyosarcoma, including Hilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).